Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion AntibodiesLSE:FAB EV-to-FCF is -9.96 as of Aug. 01, 2026. The stock has 4 warning signs investors should review. Among 345 Biotechnology companies, Fusion Antibodies ranks worse than 289854.78% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fusion Antibodies's Enterprise Value is £12.34 Mil.
Fusion Antibodies's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was £-1.24 Mil. Therefore, Fusion Antibodies's EV-to-FCF for today is -9.96.
The historical rank and industry rank for Fusion Antibodies's EV-to-FCF or its related term are showing as below:
LSE:FAB'
s EV-to-FCF Range Over the Past 10 Years
Min: -368.25 Med: -9.87 Max: -0.26
Current: -10.97
During the past 11 years, the highest EV-to-FCF of Fusion Antibodies was -0.26. The lowest was -368.25. And the median was -9.87.
LSE:FAB's EV-to-FCF is ranked worse than 100% of 345
companies
in the Biotechnology industry
Industry Median: 14.39
vs LSE:FAB: -10.97
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fusion Antibodies's PE Ratio (TTM) for today is calculated as:
Fusion Antibodies's share price for today is £0.0975.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was £-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fusion Antibodies EV-to-FCF Related Terms
Fusion Antibodies EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fusion Antibodies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's EV-to-FCF falls into.
Fusion Antibodies's current Enterprise Value is £12.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was £-1.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a EV-to-FCF of -9.96 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fusion Antibodies and its competitors. According to the industry distribution chart, Fusion Antibodies ranks #999999 out of 345 companies in the Biotechnology industry.
Is Fusion Antibodies' EV-to-FCF too high?
Fusion Antibodies' current EV-to-FCF is -9.96. Based on the distribution chart, Fusion Antibodies ranks #999999 out of 345 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Fusion Antibodies' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #999999 out of 345 companies for EV-to-FCF. This places Fusion Antibodies in the lower half of its industry. The industry median EV-to-FCF is 14.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.39, based on 345 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current EV-to-FCF is -9.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.10 — trading 143.8% above its estimated fair value. The current EV-to-FCF is -9.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current EV-to-FCF is -9.96 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
